Last reviewed · How we verify
oral hypoglycemic agents
oral hypoglycemic agents is a Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors) Small molecule drug developed by Queen Elizabeth II Health Sciences Centre. It is currently FDA-approved for Type 2 diabetes mellitus.
Oral hypoglycemic agents lower blood glucose levels through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction.
Oral hypoglycemic agents lower blood glucose levels through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | oral hypoglycemic agents |
|---|---|
| Sponsor | Queen Elizabeth II Health Sciences Centre |
| Drug class | Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a broad drug class rather than a single agent, encompassing multiple mechanistic approaches: sulfonylureas and meglitinides stimulate pancreatic beta cells to release insulin; biguanides (metformin) reduce hepatic glucose production and improve peripheral insulin sensitivity; thiazolidinediones enhance insulin sensitivity in muscle and adipose tissue; and newer agents like DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors work through incretin enhancement or renal glucose excretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight gain
- Lactic acidosis (biguanides)
- Hepatotoxicity (thiazolidinediones)
Key clinical trials
- A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents (PHASE2)
- Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy (PHASE4)
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Insulin Use and Respiratory Muscle Strength in Type 2 Diabetes
- Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral hypoglycemic agents CI brief — competitive landscape report
- oral hypoglycemic agents updates RSS · CI watch RSS
- Queen Elizabeth II Health Sciences Centre portfolio CI
Frequently asked questions about oral hypoglycemic agents
What is oral hypoglycemic agents?
How does oral hypoglycemic agents work?
What is oral hypoglycemic agents used for?
Who makes oral hypoglycemic agents?
What drug class is oral hypoglycemic agents in?
What development phase is oral hypoglycemic agents in?
What are the side effects of oral hypoglycemic agents?
Related
- Drug class: All Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors) drugs
- Manufacturer: Queen Elizabeth II Health Sciences Centre — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing